To provide more flexible treatment options for opioid use disorder among the incarcerated, San Mateo County Health’s Correctional Health Services has adopted Brixadi, a long-acting injectable buprenorphine, as part of its Medication Assisted Treatment program for at risk individuals in San Mateo County’s correctional facilities, according to the county.

Buprenorphine reduces cravings and withdrawal symptoms. Unlike daily tablets or strips, Brixadi provides steady relief in weekly or monthly doses. This flexibility gives health care providers more options to meet each patient’s needs and offers stability even in the unpredictable environment of correctional facilities, where release dates and transfers often come with little notice, according to the county.

Recommended for you

(0) comments

Welcome to the discussion.

Keep the discussion civilized. Absolutely NO personal attacks or insults directed toward writers, nor others who make comments.
Keep it clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't threaten. Threats of harming another person will not be tolerated.
Be truthful. Don't knowingly lie about anyone or anything.
Be proactive. Use the 'Report' link on each comment to let us know of abusive posts.
PLEASE TURN OFF YOUR CAPS LOCK.
Anyone violating these rules will be issued a warning. After the warning, comment privileges can be revoked.

Thank you for visiting the Daily Journal.

Please purchase a Premium Subscription to continue reading. To continue, please log in, or sign up for a new account.

We offer one free story view per month. If you register for an account, you will get two additional story views. After those three total views, we ask that you support us with a subscription.

A subscription to our digital content is so much more than just access to our valuable content. It means you’re helping to support a local community institution that has, from its very start, supported the betterment of our society. Thank you very much!

Want to join the discussion?

Only subscribers can view and post comments on articles.

Already a subscriber? Login Here